NCT03500991View on ClinicalTrials.gov

HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 26, 2018

Primary Completion Date

July 26, 2025

Study Completion Date

July 26, 2039

Conditions
Central Nervous System Tumor, PediatricGliomaEpendymomaMedulloblastomaGerm Cell TumorAtypical Teratoid/Rhabdoid TumorPrimitive Neuroectodermal TumorChoroid Plexus CarcinomaPineoblastoma
Interventions
BIOLOGICAL

HER2-specific chimeric antigen receptor (CAR) T cell

Autologous CD4 and CD8 T cells lentivirally transduced to express a HER2 specific chimeric antigen receptor (CAR) and EGFRt given via indwelling central nervous system (CNS) catheter

Trial Locations (1)

98105

Seattle Children's Hospital, Seattle

All Listed Sponsors
lead

Seattle Children's Hospital

OTHER